A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden
J. Andersson(Sophiahemmet Hospital), Jonas Bergh(Karolinska Institutet), Gudrun Greim(Uppsala University Hospital), Barbro Linderholm(Karolinska University Hospital), Henrik Lindman(Uppsala University), Sigrid Klaar(Uppsala University Hospital), Ásgerður Sverrisdóttir(Uppsala University Hospital), Jan Tennvall(Uppsala University Hospital), Dagny Pettersson-Sköld(Uppsala University Hospital), Birgitta Lindh(Uppsala University Hospital), Martin Söderberg(Uppsala University Hospital), Lena Tennvall-Nittby(Uppsala University Hospital)
Cited by 22
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k